Display Options:
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Angioedemas, Hereditary
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Platelet-derived growth factor receptor alpha inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Glioma; Leukemia, Mast-Cell; Mastocytosis, Systemic; Gastrointestinal Stromal Tumors; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Gonadotropin-releasing hormone receptor antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Endometriosis; Leiomyoma; Pain; Prostatic Neoplasms, Castration-Resistant; Neoplasms; Prostatic Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Breast Neoplasms; Carcinoma, Hepatocellular; Friedreich Ataxia; Neoplasms; Colorectal Neoplasms; Conjunctivitis, Allergic; Crohn Disease; Cytomegalovirus Infections; Fever; Malaria, Falciparum; Malaria, Vivax; Schistosomiasis; Schistosomiasis haematobia; Severe Acute Respiratory Syndrome; Malaria
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Platelet-derived growth factor receptor alpha inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Gastrointestinal Stromal Tumors; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Dopamine receptors; D2 & D3 antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Depressive Disorder, Major; Obsessive-Compulsive Disorder; Renal Insufficiency, Chronic; Bipolar Disorder; Nausea; Anxiety; Dementia; Depressive Disorder; Schizophrenia; Postoperative Nausea and Vomiting; Psychotic Disorders
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Serotonin 1f (5-HT1f) receptor agonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Substance-Related Disorders; Migraine Disorders
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: RNA-directed RNA polymerase L inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Pneumonia, Viral; Hemorrhagic Fever, Ebola; Respiratory Distress Syndrome; Severe Acute Respiratory Syndrome; Virus Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Orexin receptor 1 antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Kidney Diseases; Liver Diseases; Sleep Apnea, Obstructive; Sleep Disorders, Circadian Rhythm; Alcoholism; Sleep Wake Disorders; Sleep Initiation and Maintenance Disorders
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Androgen Receptor antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Alopecia; Acne Vulgaris
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Osmotic agent
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Constipation
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Diagnostic agent
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Alzheimer Disease; Chronic Traumatic Encephalopathy; Cognitive Dysfunction
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Diagnostic agent
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Breast Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: DNA negative modulator
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Carcinoid Tumor; Colorectal Neoplasms; Endometrial Neoplasms; Glioblastoma; Leiomyosarcoma; Leukemia; Sarcoma, Ewing; Stomach Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Mesothelioma; Pancreatic Neoplasms; Sarcoma; Ovarian Neoplasms; Neoplasms; Small Cell Lung Carcinoma
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Alzheimer Disease
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Cocaine-Related Disorders; Spasms, Infantile; Epilepsies, Myoclonic; Epilepsy; Obesity
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Fibroblast growth factor receptor 1 inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Glioblastoma; Myeloproliferative Disorders; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms; Cholangiocarcinoma; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Kidney Diseases; Liver Diseases; Cushing Syndrome; Essential Hypertension; Hyperaldosteronism; Hypertension; Pituitary ACTH Hypersecretion; Adrenal Gland Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Liver Diseases; Severe Acute Respiratory Syndrome; Colitis, Ulcerative; Crohn Disease; Multiple Sclerosis; Immune System Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Tyrosine-protein kinase SRC inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Leukemia, Myeloid, Acute; Lymphoma; Prostatic Neoplasms, Castration-Resistant; Keratosis, Actinic
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Beta-3 adrenergic receptor agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Hypertension; Irritable Bowel Syndrome; Urinary Bladder, Overactive; Urinary Incontinence; Urinary Incontinence, Urge
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Catechol O-methyltransferase inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Parkinson Disease
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Receptor protein-tyrosine kinase erbB-2 inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Diseases; Hemangiosarcoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Brain Neoplasms; Breast Neoplasms; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Copper sequestering agent
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Ectoparasitic Infestations; Lice Infestations
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Protein farnesyltransferase inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Astrocytoma; Central Nervous System Neoplasms; Colorectal Neoplasms; Gliosarcoma; Head and Neck Neoplasms; Lymphoma; Breast Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Neoplasms; Ovarian Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Hepatitis D; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Neoplasm Metastasis; Progeria
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Mu opioid receptor agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Acute Pain; Pain
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Supplement
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Amyotrophic Lateral Sclerosis; Ataxia Telangiectasia; Glycogen Storage Disease Type V; Glycogen Storage Disease Type VII; Huntington Disease; Hypoadrenocorticism, Familial; Rett Syndrome
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: DNA inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Neuroblastoma; Trypanosomiasis, African; Chagas Disease; Leishmaniasis; Trypanosomiasis
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Envelope polyprotein GP160 inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: HIV Infections; Virus Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Multiple Myeloma; Prostatic Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Lymphoma, Follicular; Sarcoma; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Carcinoma, Medullary; Carcinoma, Non-Small-Cell Lung; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: GABA-A receptor; anion channel positive allosteric modulator
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Liver Diseases; Epilepsies, Partial; Epilepsy; Seizures
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Cytidine deaminase inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Lymphoma, T-Cell, Peripheral; Neoplasms; Prostatic Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Kelch-like ECH-associated protein 1 inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis